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Abstract
Hepatocellular carcinoma (HCC) is the leading cause of 
deaths in patients with hepatitis B or C, and its incidence 
has increased considerably over the past decade and is still 
on the rise. Liver transplantation (LT) provides the best 
chance of cure for patients with HCC and liver cirrhosis. 
With the implementation of the MELD exception system 
for patients with HCC waitlisted for LT, the number of 
recipients of LT is increasing, so is the number of patients 
who have recurrence of HCC after LT. Treatments for 
intrahepatic recurrence after transplantation and after 
other kinds of surgery are more or less the same, but 
long-term cure of posttransplant recurrence is rarely 
seen as it is a “systemic” disease. Nonetheless, surgical 
resection has been shown to be effective in prolonging 
patient survival despite the technical difficulty in resecting 
graft livers. Besides surgical resection, different kinds 
of treatment are also in use, including transarterial 
chemoembolization, radiofrequency ablation, high-
intensity focused ultrasound ablation, and stereotactic 
body radiation therapy. Targeted therapy and modulation 
of immunosuppressants are also adopted to treat the 
deadly disease.
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Core tip: The management of recurrent hepatocellular 
carcinoma (HCC) after liver transplantation (LT) seems to 
be a losing battle. Nonetheless, tremendous efforts have 
been made to combat this deadly disease. Intrahepatic 
recurrence may be treated by resection, which has 
some survival benefits as shown by small clinical trials. 
Other kinds of therapy including high-intensity focused 
ultrasound (HIFU) ablation, radiofrequency ablation 
(RFA) and transarterial chemoembolization (TACE) are 
also in use. HIFU ablation has been shown to produce 
better results when compared with RFA and TACE. 
The efficacy of systemic and targeted therapies for 
multiple recurrences is under investigation. Early results 
have suggested that the combination of sorafenib with 
mammalian target of rapamycin inhibitors may be useful 
for treating recurrent HCC after LT.
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Management of recurrent hepatocellular carcinoma after 
liver transplant
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most 
common malignant tumor, the third leading cause of 
cancer-related deaths, and the first leading cause of 
deaths in patients with hepatitis B or C, and its incidence 
has increased considerably over the past decade and 
is still on the rise[1-3]. There are different modalities for 
treating HCC and underlying liver cirrhosis, but liver 
transplantation (LT) is the ultimate solution[4]. Various 
patient selection criteria for LT have been introduced 
with the hope that as many patients as possible can 
benefit from the treatment while patient survival is 
not compromised. Mazzaferro et al[5] introduced the 
Milan criteria (solitary tumor ≤ 5 cm, or ≤ 3 tumors 
with each measuring < 3 cm) on the basis of a 
retrospective study of 48 patients who received LT for 
HCC. In the study, a 75% overall survival and an 83% 
recurrence-free survival were achieved in LT recipients 
chosen according to the Milan criteria at 4 years after 
transplantation. A set of modestly expanded criteria 
was developed by the University of California, San 
Francisco (UCSF). Yao et al[6] showed that HCC patients 
selected for LT according to the UCSF criteria (solitary 
tumor ≤ 6.5 cm, or ≤ 3 nodules with the largest lesion 
≤ 4.5 cm and a total tumor diameter ≤ 8 cm) had 
survival rates of 90% and 75.2% at 1 year and 5 years 
respectively. However, discrepancy between radiological 
results and pathological results of tumor characteristics 
is not uncommon. A 30%-50% discrepancy rate has 
been reported[6,7].
In Hong Kong, about 8% of the population are 
carriers of hepatitis B virus (HBV) and most of the 
cases of HCC are caused by HBV. A survey found that 
about 10.4% of male adults and 7.7% of female adults 
were positive of hepatitis B surface antigen (surveillance 
of viral hepatitis in Hong Kong - 2010 update report. 
Hong Kong SAR: Department of Health, 2011). On the 
other hand, the numbers of carriers of hepatitis C virus 
(HCV) are rising in Japan and the United States. In 
these places where hepatitis C is epidemic, there is a 
surge of HCV-related liver cirrhosis and HCC[8,9].
Even though HCC patients are selected for LT accord-
ing to standard criteria, 10%-60% of them will have 
disease recurrence. Some of them will develop recurrence 
2 years or even 5 years after transplantation[10]. With the 
adoption of the MELD exception system for HCC patients 
waitlisted for LT, more LTs are performed for HCC. Hong 
Kong adopted the system in 2009[11], and nowadays 
HCC accounts for one third of LTs in Hong Kong. As a 
corollary, the incidence of HCC recurrence after LT is 
on the increase in places where the system is adopted. 
Recurrence of HCC after LT is notoriously difficult to 
manage. Here is a review of the treatment options 
available for this challenging situation, trying to shed 
some light on its management.
RISK FACTORS FOR HCC RECURRENCE
Post-LT HCC recurrence occurs at a rate of 13%-27%[10,12]. 
It was reported that 5% of patients developed late (after 
5 years) recurrence[10]. Most patient selection criteria for 
LT, including the Milan and the UCSF criteria, use tumor 
size and tumor number as surrogate markers. A meta-
analysis by Sotiropoulos et al[13] identified a number of 
risk factors for poorer patient survival after LT, which were 
venous invasion, poor tumor cell differentiation, tumor 
size and stage beyond the Milan criteria, and a high 
pretransplant serum α-fetoprotein level. Since radiological 
results and pathological results of tumor characteristics 
may differ, some centers use pretransplant serum 
α-fetoprotein level and biopsy to determine tumor cell 
differentiation and use it as a biological surrogate marker 
in patient selection criteria[14,15]. However, preoperative 
biopsy may cause tumor seeding and bleeding. Saborido 
et al[16] reported that a significantly higher chance of 
HCC recurrence came with fine-needle aspiration biopsy 
before LT (31.8% vs 5.9%, P = 0.003). In Hong Kong, 
contrast computed tomography (CT)[17] is used for tumor 
staging. Sometimes positron emission tomography (PET) 
using both radiotracers of 11C-acetate and 18F-FDG is also 
employed. In a report, dual-tracer PET had an overall 
sensitivity of 96.8% and an overall specificity of 91.7%, 
which are significantly higher than those of contrast 
CT (41.9% and 33.0% respectively; P < 0.05 in both 
cases)[18]. It was found that sources of error for contrast 
CT were related to liver cirrhosis or previous treatment, 
and there was difficulty in differentiating cirrhotic nodules 
from HCCs (39%) and in the estimation of tumor size 
(14%). There was infrequent overstaging of vascular 
invasion (4.6%) or extrahepatic metastasis (4.6%). 
Dual-tracer PET and contrast CT had a 4.7% rate of 
false-negative results. PET using the radiotracer 18F-FDG 
seems effective in detecting 18F-FDG-avid lesions and 
thus can be used as an adjunct to detect microvascular 
invasion[19]. Nonetheless, such use is still at its infancy 
and more large-scale trials are needed for its validation.
Deceased-donor LT vs living-donor LT
Living-donor LT (LDLT) has the most significant impact 
in Asia, where the issue of organ shortage is most 
extreme. The availability of LDLT has provided the 
driving force for a drastic increase in cases of LT in 
recent years. The number of LDLTs performed in Asia 
each year has increased tremendously. In 2005, LDLT 
accounted for 90% of the 1497 LTs performed in Asia 
(excluding mainland China)[20]. In Hong Kong, about 
half of the LTs are LDLTs, and more than half are for 
HCC.
To justify LDLT for HCC, it should have a survival 
outcome comparable to that of deceased-donor LT 
(DDLT). Roayaie et al[21] reported a tendency for early 
tumor recurrence after LDLT (mean: 8.7 mo) when 
compared with DDLT (mean: 19.6 mo) in a cohort of 
311 patients with histologically confirmed HCC after LT. 
Another multicenter LDLT cohort study (A2ALL) of 106 
HCC patients reported a significantly higher 3-year tumor 
recurrence rate after LDLT (29%) compared with that 
after DDLT (0%)[22]. In Hong Kong, a retrospective study 
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has been conducted to compare LDLT and DDLT in terms 
of treatment outcomes in 60 HCC patients[23]. Given the 
standard patient selection criteria based on radiological 
tumor size and number according to the UCSF criteria, 
there was an obvious selection bias for some important 
clinical characteristics in the LDLT group. Patients having 
LDLT for HCC had fewer incidental tumors, a lower rate of 
preoperative transarterial chemoembolization (TACE), a 
lower rate of salvage transplantation (with pretransplant 
resection or ablation), shorter waiting time on list, and 
a lower graft-weight-to-standard-liver-weight ratio. The 
inferior oncological outcomes in the LDLT group were 
possibly caused by more aggressive tumor behavior and 
small-for-size graft injury and regeneration[24]. Although 
the overall survival rates were comparable between 
the LDLT and DDLT groups, the cumulative 5-year HCC 
recurrence rate was significantly higher in LDLT group 
(29% vs 0%). Thus, selection of patients with early HCC 
based on standard tumor size and number for LDLT and 
DDLT may eventually result in different clinical outcomes. 
When considering a patient for an LDLT, besides a certain 
set of patient selection criteria, there are more factors 
to be taken into account, which include the unique 
nature of a living-donor graft as a dedicated gift to the 
recipient and potential donor risks, and additional clinical 
characteristics should also be considered and good 
preoperative counseling should be given to the donor and 
patient. In Hong Kong, the policy of “6-mo-wait” before 
salvage transplantation does not apply to LDLT, since 
both donors and recipients willingly accept the relatively 
higher recurrence rate with the realization that LDLT is 
their only option.
TREATMENTS FOR HCC RECURRENCE
Theoretically, all modalities for treating HCC can be 
used to treat its recurrence. Aggressive treatments can 
usually be given to patients who have satisfactory liver 
function and no widespread tumor cell dissemination. 
However, HCC recurrence after LT is considered a 
“systemic disease”, and the efficacy of locoregional 
treatment for a systemic disease is doubtful. For LT 
recipients, the use of immunosuppressants may hinder 
wound healing and thus lead to a higher chance of 
infective complications. Variable vascular anatomy in a 
graft liver or dense adhesion at the hilum may cause 
damage to important structures during dissection. 
Difficulties may be encountered in interventional radi-
ological procedures like TACE when the catheter is 
negotiating through the arterial anastomosis. The use 
of targeted agents for post-LT HCC recurrence has not 
been validated by any large randomized trials and it may 
have adverse effects on immunocompromised patients. 
A multidisciplinary approach with the involvement of 
hepatologists, surgeons, radiologists, oncologists and 
radiation oncologists is definitely for the best interest of 
this group of patients.
Liver resection and local ablative therapy for 
intrahepatic recurrence
Catalano et al[25] reported the initial results of graft liver 
resection for graft ischemic damage in 12 patients. 
The perioperative mortality rate was high at 66.6%, 
manifesting the difficulty of graft liver resection in the 
presence of sepsis. On the other hand, Sommacale et 
al[26] reported that graft liver resection for intrahepatic 
recurrence achieved a low mortality rate and satis-
factory long-term survival with a median follow-up of 
92 mo. Nonetheless, there were only 3 patients in the 
series. According to unpublished data from the only LT 
center in Hong Kong, in 252 patients who underwent LT 
for HCC, 35 had disease recurrence. Three patients had 
only intrahepatic recurrence and underwent aggressive 
resection. This very small series had a 66.7% 3-year 
survival and 0% mortality. Actually, all reported series 
were small and the studies had a retrospective nature 
with significant selection biases. Hence, more evidence 
is needed to support graft liver resection as a good 
treatment for HCC recurrence.
Radiofrequency ablation (RFA), a local ablative 
treatment, is the established treatment option for 
resectable and unresectable HCCs. Its efficacy has been 
shown to be comparable to that of partial liver resection 
in treating small HCCs[27]. It would be reasonable to 
extrapolate that RFA can be an option for treating post-
LT intrahepatic recurrence of HCC too. A case report 
showed that percutaneous RFA achieved 2-year disease-
free survival in a 65-year-old patient who had a solitary 
recurrent HCC inside the graft liver[28].
Stereotactic body radiation therapy and intra-arterial 
infusion of yttrium-90 microspheres for intrahepatic 
recurrence
Numerous advances in external-beam radiation therapy 
have allowed more accurate targeting and made 
aggressive dose-fractionation strategies possible with 
techniques such as stereotactic body radiation therapy 
(SBRT). As a kind of radiosurgery, SBRT was originally 
developed to treat intracranial malignancies. It has since 
been adopted to treat extracranial diseases. The use of 
SBRT as treatment of HCC has yet to be established, 
but it is tested by a number of clinical trials for its 
efficacy in treating unresectable and unablatable HCCs. 
Initial results showed that it achieved a local control rate 
of 87%-100%[17,29-31].
Intra-arterial infusion of yttrium-90 microspheres 
(Y-90 SIR) is an established treatment for unresectable 
HCCs[32] and has gained popularity in recent years. It is 
often used to treat advanced HCC, especially in patients 
with a large tumor burden, suboptimal performance 
status, or lobar portal vein thrombosis[33]. Chan et 
al[34] reported that in the treatment of primary HCC, 
it achieved a 38%-65% partial response rate and a 
median survival duration of 23 mo, which is 2.6-4.7 
times the duration seen in historic controls. In a recent 
study of 20 patients with unresectable HCCs, it achieved 
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32.1% and 26.5% respectively in the RFA group (P = 
0.61). The 1-year, 2-year, and 3-year overall survival 
rates were 96.3%, 81.5% and 69.8% respectively in 
the former, and 92.1%, 76.1% and 64.2% respectively 
in the latter (P = 0.19).
In the pilot study on HIFU ablation as a bridging 
therapy for HCC patients waitlisted for LT conducted at 
the only LT center in Hong Kong, it was found that with 
the availability of HIFU ablation, the rate of receiving 
bridging therapy increased dramatically from 39.2% 
to 80.4%. HIFU ablation and TACE achieved similar 
percentages of tumor necrosis as seen in excised livers (P 
= 0.353), and both treatments resulted in significantly 
higher necrosis rates than that in the best medical 
treatment group (P = 0.010 and 0.020)[44]. As HIFU 
ablation has been shown to be a useful bridging therapy, 
it should have great potential in the management of 
recurrent HCC after LT.
Treatment for multiple recurrence
Mammalian target of rapamycin (mTOR) inhibitors have 
been shown to have a direct antitumorigenic effect and 
to be able to inhibit cell growth[45-47]. In experimental 
models of HCC, the mTOR pathway was aberrantly 
activated in up to half of the cases. Although the 
currently available data came from retrospective studies 
and are premature, there is the hope that mTOR-based 
immunosuppressive therapy after LT will one day come 
into use[48]. The use of sorafenib, an inhibitor of multiple 
tyrosine kinases (including c-Raf and b-Raf), has been 
approved as a first-line treatment for advanced HCC[49]. 
Activation of the Ras/mitogen-activated protein kinase 
pathway is a common finding in neoplastic processes 
(including in HCC) and is a determinant for promoting 
cell proliferation and the survival of tumor cells. This 
makes sorafenib an interesting drug; its use as a 
treatment for unresectable HCCs and as an adjuvant 
treatment before and after HCC recurrence is being 
investigated[50]. A study from Spain demonstrated that 
combination therapy resulted in an overall response (in 
accordance with the Response Evaluation Criteria in Solid 
Tumors) rate of 3.8% (1/26), and there was sustained 
stabilization of disease in 13 additional cases (50.0%)[42]. 
The median overall survival was 19.3 mo (95%CI: 
13.4-25.1 mo), and the median time to progression was 
6.77 mo (95%CI: 2.3-11.1 mo). Although a few studies 
have shown that there is some evidence of synergistic 
anticancer activity, early-phase clinical studies of mTOR 
inhibitors plus sorafenib for advanced HCC reported 
ambivalent findings, which were the results of increased 
toxicity (e.g., hand-foot syndrome) in combination 
therapy[51,52]. In a recent study from Italy, the outcomes 
of sorafenib treatment for post-LT HCC recurrence 
were significantly better than those of best medical 
care [median patient survival from recurrence: 21.3 
mo vs 11.8 mo, hazard ratio (HR) = 5.2, P = 0.0009; 
median patient survival from untreatable presentation 
or progression: 10.6 mo vs 2.2 mo, HR = 21.1, P < 
an overall survival rate of 90% at a median follow-up 
period of 275 d (range: 32-677 d)[33]. However, the data 
on the use of SBRT and intra-arterial infusion of Y-90 
SIR for recurrent HCC after LT are extremely scarce. In 
the only two case reports, complete tumor necrosis was 
observed in a 52-year-old and a 42-year-old patient 
with solitary intrahepatic recurrence of HCC after a 
course of SBRT and intra-arterial infusion of Y-90 SIR 
respectively[35,36].
TACE for intrahepatic recurrence
TACE is often used as a bridging therapy for waitlisted 
patients and its results are satisfactory. Lo et al[37] 
reported that it resulted in marked tumor response, and 
the actuarial survival was significantly better in the TACE 
group (1 year: 57%, 2 years: 31%, 3 years: 26%) 
compared with the control group (1 year: 32%, 2 years: 
11%, 3 years: 3%, P = 0.002). When adjustments for 
baseline variables that were prognostic on univariate 
analysis were made with a multivariate Cox model, the 
survival benefit of TACE remained significant (relative 
risk of death: 0.49; 95%CI: 0.29-0.81; P = 0.006).
Chok et al[38] compared TACE and RFA for un-
resectable HCCs and found that they were comparable 
in terms of time to disease progression (P = 0.95) and 
overall survival (P = 0.02).
Successful outcomes of TACE therapy (with and with-
out the use of iodized oil) for the treatment of recurrent 
intrahepatic HCC after LT have been reported[39,40] 
although the studies were small and retrospective in 
nature. As said before, the transcatheter procedure can 
be technically demanding in the presence of distorted 
vasculature in a post-LT setting.
New therapy for intrahepatic recurrence
High-intensity focused ultrasound (HIFU) ablation is 
a relatively new totally extracorporeal treatment for 
unresectable HCCs. Ng et al[41] in their initial research 
reported that it achieved a primary effective treatment 
rate of 79.5% and 1-year and 3-year overall survival 
rates of 87.7% and 62.4% respectively.
Cheung et al[42] compared HIFU ablation with TACE 
and reported that HIFU ablation achieved rates of 
complete tumor response, partial tumor response, stable 
disease and progressive disease (in accordance with the 
modified Response Evaluation Criteria in Solid Tumors) 
of 50%, 7.7%, 25.6% and 7.7% respectively. As with 
TACE, the corresponding rates were 0%, 21.2%, 63.5% 
and 15.4% respectively (P < 0.0001). The 1-year, 3-year 
and 5-year survival rates achieved by HIFU ablation 
were 84.6%, 49.2% and 32.3% respectively, and those 
by TACE were 69.2%, 29.8% and 2.3% respectively (P 
= 0.001).
Chan et al[43] compared HIFU ablation with RFA in 
terms of survival. The two kinds of ablative treatment 
produced similar results. The 1-year, 2-year, and 3-year 
disease-free survival rates were 37.0%, 25.9% and 
18.5% respectively in the HIFU group, and 48.6%, 
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0.0001]. The only factor associated with survival found 
by multivariate analysis was treatment with sorafenib 
(HR = 4.0, P = 0.0325). No severe adverse event 
was registered[53]. Individualized treatment should be 
tailor-made for individual recipients, and input from 
oncologists would be of great value. However, drug 
toxicity is a major concern as shown in many studies, 
and their recommendations should not be overlooked.
Use of different immunosuppressants
It has been suggested that immunosuppressive therapy 
should switch from using non-mTOR inhibitors to using 
mTOR inhibitors. Another suggestion is that mTOR 
inhibitors can be used as an add-on. Monaco[54] found 
that the use of mTOR inhibitors might decrease the 
incidence of new malignancy after transplantation, 
mainly skin cancer.
A clinical trial by Alamo et al[55] comparing calcineurin 
inhibitors with everolimus and sirolimus for patients 
who received LT for oncological disease reported that 
the HCC recurrence rate was significantly lower and 
survival significantly prolonged in patients receiving 
either everolimus or sirolimus. A meta-analysis by Liang 
et al[56] endorsed the safety and efficacy of sirolimus-
based immunosuppression for patients who received 
LT for HCC. Pooled results of the five studies eligible 
for evaluation showed that sirolimus-based regimens 
prolonged overall survival (OR = 2.47; 95%CI: 
1.72-3.55) and decreased tumor recurrence (OR = 0.42; 
95%CI: 0.21-0.83), with no significant differences in 
acute rejection and hepatic artery thrombosis.
A United States study compared sirolimus-based 
maintenance therapy with calcineurin inhibitor treatment 
for recipients of LT for HCC and found that overall 
survival was better in the sirolimus arm[57]. Clinical trials 
examining the anticancer effects of mTOR inhibitors 
in recipients of LT for HCC have shown encouraging 
results[58]. On multivariate analysis in a large Canadian 
trial, sirolimus-based maintenance therapy was one of 
the factors associated with improved survival after LT 
for HCC (HR = 0.53, 95%CI: 0.31-0.92, P ≤ 0.05)[59].
The reported results of using these relatively new 
agents has suggested that they may prevent or reduce 
the incidence of HCC recurrence after LT, but a definite 
answer from large randomized controlled trials is still 
lacking.
CONCLUSION
Recurrence of HCC after LT is a deadly disease. 
Although there are a variety of treatment approaches, 
long-term cure is rarely seen. One of the reasons is 
that the disease is “systemic” in most of the cases, 
even if the recurrence is intrahepatic only. Effective 
adjuvant or systemic therapy has yet to be identified. A 
multidisciplinary approach with fine-tuning of treatment 
goals and objectives will definitely be beneficial, and 
development of new drugs or modification of current 
systemic agents is urgently needed.
REFERENCES
1 Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, 
Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. 
Clinical management of hepatocellular carcinoma. Conclusions 
of the Barcelona-2000 EASL conference. European Association 
for the Study of the Liver. J Hepatol 2001; 35: 421-430 [PMID: 
11592607 DOI: 10.1016/S0168-8278(01)00130-1]
2 El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The 
continuing increase in the incidence of hepatocellular carcinoma in 
the United States: an update. Ann Intern Med 2003; 139: 817-823 
[PMID: 14623619 DOI: 10.7326/0003-4819-139-10-200311180-0
0009]
3 Welker MW, Bechstein WO, Zeuzem S, Trojan J. Recurrent 
hepatocellular carcinoma after liver transplantation - an emerging 
clinical challenge. Transpl Int 2013; 26: 109-118 [PMID: 22994652 
DOI: 10.1111/j.1432-2277.2012.01562.x]
4 Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. 
Rapamycin blocks tumor progression: unlinking immunosuppression 
from antitumor efficacy. Transplantation 2002; 73: 1565-1572 
[PMID: 12042641 DOI: 10.1097/00007890-200205270-00008]
5 Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, 
Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. 
Liver transplantation for the treatment of small hepatocellular 
carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 
693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104]
6 Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, 
Ascher NL, Roberts JP. Liver transplantation for hepatocellular 
carcinoma: expansion of the tumor size limits does not adversely 
impact survival. Hepatology 2001; 33: 1394-1403 [PMID: 
11391528 DOI: 10.1053/jhep.2001.24563]
7 Ng KK, Lo CM, Chan SC, Chok KS, Cheung TT, Fan ST. Liver 
transplantation for hepatocellular carcinoma: the Hong Kong 
experience. J Hepatobiliary Pancreat Sci 2010; 17: 548-554 
[PMID: 19760139 DOI: 10.1007/s00534-009-0165-8]
8 El-Serag HB, Mason AC. Rising incidence of hepatocellular 
carcinoma in the United States. N Engl J Med 1999; 340: 745-750 
[PMID: 10072408 DOI: 10.1056/NEJM199903113401001]
9 Taura N, Yatsuhashi H, Hamasaki K, Nakao K, Daikoku M, Ueki T, 
Yano K, Matsumoto T, Ishibashi H, Eguchi K. Increasing hepatitis 
C virus-associated hepatocellular carcinoma mortality and aging: 
Long term trends in Japan. Hepatol Res 2006; 34: 130-134 [PMID: 
16426888 DOI: 10.1016/j.hepres.2005.11.007]
10 Chok KS, Chan SC, Cheung TT, Chan AC, Fan ST, Lo CM. Late 
recurrence of hepatocellular carcinoma after liver transplantation. 
World J Surg 2011; 35: 2058-2062 [PMID: 21597889 DOI: 
10.1007/s00268-011-1146-z]
11 Chan SC, Sharr WW, Chok KS, Chan AC, Lo CM. Wait and 
transplant for stage 2 hepatocellular carcinoma with deceased-
donor liver grafts. Transplantation 2013; 96: 995-999 [PMID: 
23924774 DOI: 10.1097/01.TP.0000437674.24458.6c]
12 Kornberg A, Küpper B, Tannapfel A, Katenkamp K, Thrum 
K, Habrecht O, Wilberg J. Long-term survival after recurrent 
hepatocellular carcinoma in liver transplant patients: clinical 
patterns and outcome variables. Eur J Surg Oncol 2010; 36: 
275-280 [PMID: 19857941 DOI: 10.1016/j.ejso.2009.10.001]
13 Sotiropoulos GC, Molmenti EP, Lösch C, Beckebaum S, Broelsch 
CE, Lang H. Meta-analysis of tumor recurrence after liver 
transplantation for hepatocellular carcinoma based on 1,198 cases. 
Eur J Med Res 2007; 12: 527-534 [PMID: 18024261]
14 DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral 
MS, McGilvray I, Ghanekar A, Selzner M, Greig PD, Grant DR. 
Liver transplantation for advanced hepatocellular carcinoma using 
poor tumor differentiation on biopsy as an exclusion criterion. 
Ann Surg 2011; 253: 166-172 [PMID: 21294289 DOI: 10.1097/
SLA.0b013e31820508f1]
15 Chinnakotla S, Davis GL, Vasani S, Kim P, Tomiyama K, 
Sanchez E, Onaca N, Goldstein R, Levy M, Klintmalm GB. Impact 
of sirolimus on the recurrence of hepatocellular carcinoma after 
liver transplantation. Liver Transpl 2009; 15: 1834-1842 [PMID: 
Chok KSH. Recurrent hepatocellular carcinoma after liver transplant
1147 May 18, 2015|Volume 7|Issue 8|WJH|www.wjgnet.com
19938137 DOI: 10.1002/lt.21953]
16 Saborido BP, Díaz JC, de Los Galanes SJ, Segurola CL, de Usera 
MA, Garrido MD, Elola-Olaso AM, Sánz RG, Romero CJ, Garcia 
García I, González EM. Does preoperative fine needle aspiration-
biopsy produce tumor recurrence in patients following liver 
transplantation for hepatocellular carcinoma? Transplant Proc 
2005; 37: 3874-3877 [PMID: 16386569 DOI: 10.1016/j.transproce
ed.2005.09.169]
17 Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook 
J, Johnstone PA, Cardenes HR. Stereotactic body radiotherapy for 
primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011; 
81: e447-e453 [PMID: 21645977 DOI: 10.1016/j.ijrobp.2011.04.011]
18 Cheung TT, Ho CL, Lo CM, Chen S, Chan SC, Chok KS, Fung 
JY, Yan Chan AC, Sharr W, Yau T, Poon RT, Fan ST. 11C-acetate 
and 18F-FDG PET/CT for clinical staging and selection of patients 
with hepatocellular carcinoma for liver transplantation on the basis 
of Milan criteria: surgeon’s perspective. J Nucl Med 2013; 54: 
192-200 [PMID: 23321459 DOI: 10.2967/jnumed.112.107516]
19 Cheung TT, Chan SC, Ho CL, Chok KS, Chan AC, Sharr WW, Ng 
KK, Poon RT, Lo CM, Fan ST. Can positron emission tomography 
with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose 
predict microvascular invasion in hepatocellular carcinoma? Liver 
Transpl 2011; 17: 1218-1225 [PMID: 21688383 DOI: 10.1002/
lt.22362]
20 de Villa V, Lo CM. Liver transplantation for hepatocellular 
carcinoma in Asia. Oncologist 2007; 12: 1321-1331 [PMID: 
18055852 DOI: 10.1634/theoncologist.12-11-1321]
21 Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi 
GE, Krieger NR, Schwartz ME. Recurrence of hepatocellular 
carcinoma after liver transplant: patterns and prognosis. Liver Transpl 
2004; 10: 534-540 [PMID: 15048797 DOI: 10.1002/lt.20128]
22 Fisher RA, Kulik LM, Freise CE, Lok AS, Shearon TH, Brown RS, 
Ghobrial RM, Fair JH, Olthoff KM, Kam I, Berg CL. Hepatocellular 
carcinoma recurrence and death following living and deceased donor 
liver transplantation. Am J Transplant 2007; 7: 1601-1608 [PMID: 
17511683 DOI: 10.1111/j.1600-6143.2007.01802.x]
23 Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J. Living donor 
versus deceased donor liver transplantation for early irresectable 
hepatocellular carcinoma. Br J Surg 2007; 94: 78-86 [PMID: 
17016793 DOI: 10.1002/bjs.5528]
24 Man K, Fan ST, Lo CM, Liu CL, Fung PC, Liang TB, Lee TK, 
Tsui SH, Ng IO, Zhang ZW, Wong J. Graft injury in relation to 
graft size in right lobe live donor liver transplantation: a study of 
hepatic sinusoidal injury in correlation with portal hemodynamics 
and intragraft gene expression. Ann Surg 2003; 237: 256-264 
[PMID: 12560784 DOI: 10.1097/01.SLA.0000048976.11824.67]
25 Catalano G, Urbani L, Biancofiore G, Bindi L, Boldrini A, 
Consani G, Bisà M, Campatelli A, Petruzzi P, Cioni R, Vignali C, 
Mosca F, Filipponi F. Hepatic resection after liver transplantation as 
a graft-saving procedure: indication criteria, timing and outcome. 
Transplant Proc 2004; 36: 545-546 [PMID: 15110588 DOI: 
10.1016/j.transproceed.2004.02.028]
26 Sommacale D, Dondero F, Sauvanet A, Francoz C, Durand F, 
Farges O, Kianmanesh R, Belghiti J. Liver resection in transplanted 
patients: a single-center Western experience. Transplant Proc 
2013; 45: 2726-2728 [PMID: 24034033 DOI: 10.1016/j.transproce
ed.2013.07.032]
27 Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, 
Lau WY. A prospective randomized trial comparing percutaneous 
local ablative therapy and partial hepatectomy for small 
hepatocellular carcinoma. Ann Surg 2006; 243: 321-328 [PMID: 
16495695 DOI: 10.1097/01.sla.0000201480.65519.b8]
28 Ho CK, Chapman WC, Brown DB. Radiofrequency ablation 
of recurrent hepatocellular carcinoma in a patient after liver 
transplantation: two-year follow-up. J Vasc Interv Radiol 2007; 18: 
1451-1453 [PMID: 18003999 DOI: 10.1016/j.jvir.2007.07.017]
29 Cárdenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen 
TE, Henderson MA, Schefter TE, Tudor K, Deluca J, Johnstone 
PA. Phase I feasibility trial of stereotactic body radiation therapy 
for primary hepatocellular carcinoma. Clin Transl Oncol 2010; 12: 
218-225 [PMID: 20231127 DOI: 10.1007/s12094-010-0492-x]
30 Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, 
Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, 
Sherman M, Knox JJ, Dawson LA. Sequential phase I and II 
trials of stereotactic body radiotherapy for locally advanced 
hepatocellular carcinoma. J Clin Oncol 2013; 31: 1631-1639 
[PMID: 23547075 DOI: 10.1200/JCO.2012.44.1659]
31 Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, Bae SH, 
Jung da H, Kim KB, Lee DH, Han CJ, Kim J, Park SC, Kim YH. 
Stereotactic body radiation therapy for inoperable hepatocellular 
carcinoma as a local salvage treatment after incomplete 
transarterial chemoembolization. Cancer 2012; 118: 5424-5431 
[PMID: 22570179 DOI: 10.1002/cncr.27533]
32 Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha 
JF, Clary BM, Covey A, Curley SA, D’Angelica MI, Davila R, 
Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, 
Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem 
R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, 
Yen Y, Zhu AX. NCCN clinical practice guidelines in oncology: 
hepatobiliary cancers. J Natl Compr Canc Netw 2009; 7: 350-391 
[PMID: 19406039]
33 Padia SA, Kwan SW, Roudsari B, Monsky WL, Coveler A, Harris 
WP. Superselective yttrium-90 radioembolization for hepatocellular 
carcinoma yields high response rates with minimal toxicity. J 
Vasc Interv Radiol 2014; 25: 1067-1073 [PMID: 24837982 DOI: 
10.1016/j.jvir.2014.03.030]
34 Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective 
study regarding the complications of transcatheter intraarterial 
lipiodol chemoembolization in patients with hepatocellular 
carcinoma. Cancer 2002; 94: 1747-1752 [PMID: 11920537 DOI: 
10.1002/cncr.10407]
35 Rivera L, Giap H, Miller W, Fisher J, Hillebrand DJ, Marsh 
C, Schaffer RL. Hepatic intra-arterial infusion of yttrium-90 
microspheres in the treatment of recurrent hepatocellular carcinoma 
after liver transplantation: a case report. World J Gastroenterol 
2006; 12: 5729-5732 [PMID: 17007031]
36 Mazloom A, Hezel AF, Katz AW. Stereotactic body radiation 
therapy as a bridge to transplantation and for recurrent disease in the 
transplanted liver of a patient with hepatocellular carcinoma. Case Rep 
Oncol 2014; 7: 18-22 [PMID: 24575010 DOI: 10.1159/000357801]
37 Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, 
Wong J. Randomized controlled trial of transarterial lipiodol 
chemoembolization for unresectable hepatocellular carcinoma. 
Hepatology 2002; 35: 1164-1171 [PMID: 11981766 DOI: 10.1053/
jhep.2002.33156]
38 Chok KS, Ng KK, Poon RT, Lam CM, Yuen J, Tso WK, Fan ST. 
Comparable survival in patients with unresectable hepatocellular 
carcinoma treated by radiofrequency ablation or transarterial 
chemoembolization. Arch Surg 2006; 141: 1231-1236 [PMID: 
17178966 DOI: 10.1001/archsurg.141.12.1231]
39 Ko HK, Ko GY, Yoon HK, Sung KB. Tumor response to 
transcatheter arterial chemoembolization in recurrent hepatocellular 
carcinoma after living donor liver transplantation. Korean J Radiol 
2009; 8: 320-327 [PMID: 17673843 DOI: 10.3348/kjr.2007.8.4.320]
40 Zhou B, Shan H, Zhu KS, Jiang ZB, Guan SH, Meng XC, Zeng 
XC. Chemoembolization with lobaplatin mixed with iodized oil for 
unresectable recurrent hepatocellular carcinoma after orthotopic 
liver transplantation. J Vasc Interv Radiol 2010; 21: 333-338 
[PMID: 20116286 DOI: 10.1016/j.jvir.2009.11.006]
41 Ng KK, Poon RT, Chan SC, Chok KS, Cheung TT, Tung 
H, Chu F, Tso WK, Yu WC, Lo CM, Fan ST. High-intensity 
focused ultrasound for hepatocellular carcinoma: a single-center 
experience. Ann Surg 2011; 253: 981-987 [PMID: 21394012 DOI: 
10.1097/SLA.0b013e3182128a8b]
42 Cheung TT, Poon RT, Jenkins CR, Chu FS, Chok KS, Chan 
AC, Tsang SH, Dai WC, Yau TC, Chan SC, Fan ST, Lo CM. 
Survival analysis of high-intensity focused ultrasound therapy vs. 
transarterial chemoembolization for unresectable hepatocellular 
carcinomas. Liver Int 2014; 34: e136-e143 [PMID: 24451026 DOI: 
10.1111/liv.12474]
Chok KSH. Recurrent hepatocellular carcinoma after liver transplant
1148 May 18, 2015|Volume 7|Issue 8|WJH|www.wjgnet.com
43 Chan AC, Cheung TT, Fan ST, Chok KS, Chan SC, Poon RT, Lo 
CM. Survival analysis of high-intensity focused ultrasound therapy 
versus radiofrequency ablation in the treatment of recurrent 
hepatocellular carcinoma. Ann Surg 2013; 257: 686-692 [PMID: 
23426335 DOI: 10.1097/SLA.0b013e3182822c02]
44 Chok KS, Cheung TT, Lo RC, Chu FS, Tsang SH, Chan AC, 
Sharr WW, Fung JY, Dai WC, Chan SC, Fan ST, Lo CM. Pilot 
study of high-intensity focused ultrasound ablation as a bridging 
therapy for hepatocellular carcinoma patients wait-listed for 
liver transplantation. Liver Transpl 2014; 20: 912-921 [PMID: 
24753206 DOI: 10.1002/lt.23892]
45 Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer 
therapy. Nat Rev Cancer 2004; 4: 335-348 [PMID: 15122205 DOI: 
10.1038/nrc1362]
46 Koehl GE, Andrassy J, Guba M, Richter S, Kroemer A, Scherer 
MN, Steinbauer M, Graeb C, Schlitt HJ, Jauch KW, Geissler EK. 
Rapamycin protects allografts from rejection while simultaneously 
attacking tumors in immunosuppressed mice. Transplantation 
2004; 77: 1319-1326 [PMID: 15167584 DOI: 10.1097/00007890-2
00405150-00002]
47 Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, 
Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch 
KW, Geissler EK. Rapamycin inhibits primary and metastatic 
tumor growth by antiangiogenesis: involvement of vascular 
endothelial growth factor. Nat Med 2002; 8: 128-135 [PMID: 
11821896 DOI: 10.1038/nm0202-128]
48 Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, 
Garralda E, Testillano M, Herrero I, Matilla A, Sangro B. Efficacy 
and safety of sorafenib in combination with mammalian target 
of rapamycin inhibitors for recurrent hepatocellular carcinoma 
after liver transplantation. Liver Transpl 2012; 18: 45-52 [PMID: 
21932373 DOI: 10.1002/lt.22434]
49 Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, 
de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta 
C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath 
I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, 
Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl 
J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/
NEJMoa0708857]
50 Kudo M. Adjuvant therapy after curative treatment for hepatocellular 
carcinoma. Oncology 2011; 81 Suppl 1: 50-55 [PMID: 22212936 
DOI: 10.1159/000333259]
51 Finn RS, Poon RT, Yau T, Klümpen HJ, Chen LT, Kang YK, 
Kim TY, Gomez-Martin C, Rodriguez-Lope C, Kunz T, Paquet 
T, Brandt U, Sellami D, Bruix J. Phase I study investigating 
everolimus combined with sorafenib in patients with advanced 
hepatocellular carcinoma. J Hepatol 2013; 59: 1271-1277 [PMID: 
23928403 DOI: 10.1016/j.jhep.2013.07.029]
52 Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, 
Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky 
JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, 
Benson AB, Venook AP. Temsirolimus combined with sorafenib 
in hepatocellular carcinoma: a phase I dose-finding trial with 
pharmacokinetic and biomarker correlates. Ann Oncol 2013; 24: 
1900-1907 [PMID: 23519998 DOI: 10.1093/annonc/mdt109]
53 Sposito C, Mariani L, Germini A, Flores Reyes M, Bongini M, 
Grossi G, Bhoori S, Mazzaferro V. Comparative efficacy of sorafenib 
versus best supportive care in recurrent hepatocellular carcinoma after 
liver transplantation: a case-control study. J Hepatol 2013; 59: 59-66 
[PMID: 23500153 DOI: 10.1016/j.jhep.2013.02.026]
54 Monaco AP. The role of mTOR inhibitors in the management of 
posttransplant malignancy. Transplantation 2009; 87: 157-163 
[PMID: 19155967 DOI: 10.1097/TP.0b013e318193886e]
55 Alamo JM, Bernal C, Marín LM, Suárez G, Serrano J, Barrera 
L, Sousa JM, Padillo FJ, Gómez-Bravo MA. Antitumor efficacy 
of mammalian target of rapamycin inhibitor therapy in liver 
transplant recipients with oncological disease: a case-control study. 
Transplant Proc 2012; 44: 2089-2092 [PMID: 22974919 DOI: 
10.1016/j.transproceed.2012.07.079]
56 Liang W, Wang D, Ling X, Kao AA, Kong Y, Shang Y, Guo Z, He 
X. Sirolimus-based immunosuppression in liver transplantation for 
hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012; 18: 
62-69 [PMID: 21964956 DOI: 10.1002/lt.22441]
57 Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba 
A, Kam I. Sirolimus-based immunosuppression following liver 
transplantation for hepatocellular carcinoma. Liver Transpl 2008; 
14: 633-638 [PMID: 18324656 DOI: 10.1002/lt.21420]
58 Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, 
Gutfreund K, Ma MM, Mason AL, Wong WW, Bain VG, 
Kneteman NM. De novo sirolimus-based immunosuppression 
after liver transplantation for hepatocellular carcinoma: long-term 
outcomes and side effects. Transplantation 2007; 83: 1162-1168 
[PMID: 17496530 DOI: 10.1097/01.tp.0000262607.95372.e0]
59 Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. 
Sirolimus-based immunosuppression is associated with increased 
survival after liver transplantation for hepatocellular carcinoma. 
Hepatology 2010; 51: 1237-1243 [PMID: 20187107 DOI: 10.1002/
hep.23437]
P- Reviewer: Dehghani SM, Frenette C, Kubota K, Silva G 
S- Editor: Ji FF    L- Editor: A    E- Editor: Liu SQ 
Chok KSH. Recurrent hepatocellular carcinoma after liver transplant
                                      © 2015 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
